ClinicalTrials.gg
RecruitingNCT06646653EVEUpdated Mar 30, 2026

EVE TRIAL , ALMA SYSTAM

A Phase 3 interventional study of Alma System in Postpartum Haemorrhage (PPH), PPH and Postpartum Hemorrhage (Primary), sponsored by ResQ Medical Ltd. Recruiting at 2 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by ResQ Medical Ltd · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Postpartum Hemorrhage with a site in United States — 10 open to participants now, 12 under way, 3 of them phase 3. Postpartum Hemorrhage · United States.

Planned enrollment
28th of 46
50 · median 65
Started
2026
the only one that year
Phase 3
6 of 65
3 open now
Primary completion
2027-01
later than 5 of 11 live
Registered
60th of 65
by date

Among the 65 studies in Postpartum Hemorrhage with a site in United States, this one is the 28th largest by planned enrollment of the 46 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 60th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

10 of the 65 studies in Postpartum Hemorrhage with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Postpartum Hemorrhage with a site in United States, or all of them as a file.
02

Study summary

abnormal bleeding after childbirth. This condition is called abnormal bleeding and becomes a condition known as postpartum hemorrhage (PPH) when worsens. Abnormal bleeding is defined as the loss of more than 500 milliliters (about two cups) of blood after a vaginal birth, or more than 1,000 milliliters (about four cups) after a cesarean section. It is a serious and potentially life-threatening complication that requires immediate medical treatment.

What you need to know:

  • Signing this form does not mean you will have an emergency postpartum bleeding.
  • We will only include you in the study IF abnormal bleeding happens after your birth.
  • If abnormal bleeding does happen, your doctors will first try the usual treatments that work in accordance with the hospital's PPH protocol.
  • The study device (called Alma system) would only be used if the usual treatments do not stop the bleeding.

Treatment Schedule - Recruitment \& Consenting

  • Screening and enrolment.
  • Treatment of PPH with Alma system.
  • Alma Survey
  • Follow up examination post treatment procedure (after removal of Alma system and before subject discharge from the hospital).
  • 6-week postpartum follow-up examination.
Read the detailed description

Visit 1 - Before Birth (Screening and Enrollment)

No study-related procedures will be done until you have reviewed and signed this consent form. The screening visit tests and procedures are done to see if you are eligible to be in the study. This visit could take a few hours to complete. During this visit, we will collect important background information and perform a physical examination. The following tests and procedures will take place:

  • A purple bracelet will be placed on your wrist to indicate to the clinical team that you have signed this informed consent form. This helps ensure that, in the event of abnormal bleeding, you can be quickly identified as a participant in the study
  • Demographic information: Including date of birth, race, height, weight, and number of previous childbirths.
  • Medical History: This includes your past and current health conditions, with particular focus on gynecological issues, prior surgeries, current medications, and any known allergies
  • Physical examination: including vital signs such as blood pressure and heart rate.
  • Blood tests: including Complete Blood Count (CBC) and Coagulation Panel.

Neither you nor your health care plan/insurance carrier will be billed for the collection of the information that will be used for this study.

Visit 2 - Diagnosis and Treatment of Abnormal Bleedong and Post-Partum Hemorrhage (PPH) with the Alma System If you experience abnormal bleeding or postpartum hemorrhage (PPH), your doctor will evaluate all possible causes and follow the hospital's standard treatment protocols. Initial treatment typically includes medications to help the uterus contract and reduce bleeding, as well as manual uterine massage, as recommended by your medical team.

If those treatments do not work, your doctor may decide to use the Alma system to help control or reduce the bleeding.

Once the Alma system is in place, the medical team will perform an ultrasound to check that the device is placed correctly and remains stable.

In addition, the following data will be collected from the treating team:

  • A questionnaire about how easy the Alma System was to use (Usability Questionnaire).
  • The amount of time it took to use the Alma System.
  • Your symptoms and any adverse events (your overall health).
  • An evaluation of how well the Alma System worked (treatment evaluation). Visit 3 - Post Treatment Follow-up Examination Before you leave the hospital and after removal of the Alma system, your doctor will perform a follow-up exam.s,

This will include:

  • Physical examination, blood tests, vital signs such as blood pressure and heart rate.
  • Your symptoms and any adverse events (your overall health).

Visit 4 - 6-Week Postpartum Follow-up Examination and Study Completion

A final study follow-up assessment will take place at your routine 6-week postpartum follow-up check-up. The following assessments will be performed:

  • Physical Examination
  • Review of any adverse events Note: If you are unable to return for your routine 6-week postpartum check-up after three documented contact attempts, the study team will follow-up by phone to ask about your overall health since discharge. Any complaints will be investigated.
03

Conditions studied

  • Postpartum Haemorrhage (PPH)
  • PPH
  • Postpartum Hemorrhage (Primary)

Browse trials for

Keywords

  • Alma System
  • postpartum hemorrhage
  • pph
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

  1. Adult Female, 18 years of age or older at time of consent.
  2. Able to understand and provide to participate in the study.
  3. Diagnosis of abnormal postpartum uterine bleeding or hemorrhage with suspected atony within 24 hours after vaginal or c-section delivery.
  4. EBL, determined when investigator is ready to have the Alma peel pack opened:

    Vaginal delivery: 500 - 1500 ml EBL or C-section delivery 1000 - 1500 ml EBL

  5. Failed intervention of uterotonics and uterine massage/bimanual uterine massage to stop bleeding.

Note: Uterotonic administration may continue concomitantly with and post Alma use, as long as such use does not exceed the maximum dose of the drug 10.3.2 Exclusion Criteria

  1. EBL >1500ml, to be determined when investigator is ready to have the Alma peel pack opened.
  2. Delivery at a gestational age \< 34 weeks.
  3. For Cesarean-sections birth: Cervix \< 3 cm dilated before use of Alma.
  4. PPH that the investigator determines to require more aggressive treatment, including any of the following:

    1. hysterectomy;
    2. b-lynch suture;
    3. uterine artery embolization or ligation;
    4. hypogastric ligation.
  5. Known uterine anomaly.
  6. Ongoing intrauterine pregnancy.
  7. Placenta abnormality including any of the following:

    1. known placenta accreta;
    2. retained placenta with known risk factors for placenta accreta (e.g. history of prior uterine surgery, including prior c-section and placenta previa);
    3. retained placenta without easy manual removal.
  8. Known uterine rupture.
  9. Unresolved uterine inversion.
  10. Subject has undergone intrauterine balloon therapy or uterine packing or use of other negative pressure system(s) for tamponade treatment of this PPH prior to use of Alma.
  11. Current cervical cancer.
  12. Current purulent infection of vagina, cervix, uterus.
  13. Diagnosis of coagulopathy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Participant group

    Woman who developed PPH after vaginal or caesarean delivery and first line interventions have been attempted and failed, and to which the Alma System was applied

    Device: Alma System

Interventions

  • DeviceAlma System

    Subjects diagnosed with abnormal bleeding or postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.

    Also known as: Obstetric-gynecologic specialized manual instrument, Vacuum induced heamorrhage control

06

What researchers measure

Primary outcomes

  1. Incidence of safety events

    Incidence, severity and seriousness of device-related Adverse Events (AEs).

    Time frame: 6 weeks

  2. PPH control

    Control of postpartum hemorrhage, defined as the avoidance of non-surgical, second-line or surgical intervention to control uterine hemorrhage after the use of the Alma System per the Instructions for Use.

    Time frame: Procedure

Secondary outcomes

  1. Hemorrhage control

    Time to control hemorrhage, defined as the time from turning on the vacuum source until the time the first of any of the following occurs: * there is no blood being collected in the tubing or canister, or * the blood loss is observed as leveled off in the canister, or * blood loss is at a rate of \< 500 ml in 24 hours.

    Time frame: minutes to hours

  2. Surgical Intervention

    Rate of surgical intervention required to control PPH after Alma use.

    Time frame: minutes to hours

  3. Non Surgical intervention

    Rate of non-surgical intervention as secondary medications (e.g.uterotonics, pain medications) required to control PPH after Alma use .

    Time frame: minutes to hours

  4. Blood product transfusion

    Rate of blood product transfusion required after Alma use, and number of transfusion units when administered.

    Time frame: hours to days

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

Of 20 phase 3 interventional studies under Postpartum Hemorrhage, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 17, 2024
StartActual
Jan 11, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Apr 2027
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06646653
Lead sponsor
ResQ Medical Ltd
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Jan 11, 2026
Primary completion
Jan 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Mar 30, 2026

Study contacts

Yael Corcos, RN
Contact
yael@resq-med.com
972-548106010
Scott Chudnoff, MD
study chair · Maimonides Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion